ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluorouracil

Also written as “5-Fluorouracil”, “fluorouracil” and “5-fluorouracil”.

Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Neoplasms · Head and Neck Neoplasms · Stomach Neoplasms, led by 12 companies.

Drug pageFluorouracil: every studyMany companies study it; this page follows only the 34 they lead. All 763 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 14, 200634 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi160 open or runningphase 4since Sep 14, 2006Jan 6, 2001none ahead
Pfizerits history only51 open or runningphase 3since Jan 28, 2000Jan 28, 2000none ahead
Jiangsu HengRui Medicineits history only21 open or runningphase 3since Feb 20, 2023Mar 8, 2021none ahead
Otsukaits history only20 open or runningphase 3since Jun 2, 2000Jun 2, 2000none ahead
Prologue Research Internationalits history only20 open or runningphase 3since Jun 5, 2003May 6, 2001none ahead
Almirallits history only10 open or runningphase 3since Nov 10, 2014Nov 10, 2014none ahead
CbsBioscienceits history only10 open or runningphase 2since Nov 10, 2016Nov 10, 2016none ahead
Encube Ethicals Pvt.its history only10 open or runningphase 3since Sep 23, 2021Sep 23, 2021none ahead
HealthCare Global Enterpriseits history only10 open or runningphase 2since Sep 29, 2016Sep 29, 2016none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 3since Feb 25, 2019Feb 25, 2019none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, Baili-Bio (Chengdu) Pharmaceutical, Quintiles, Takeda, Almirall Hermal and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2001First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT00008281 · United States, Canada
  2. Nov 28, 2005Phase 2 study in Esophageal NeoplasmsNCT00259402 · 41 enrolled · Spain
  3. Dec 2, 2005Phase 3 study in Head and Neck NeoplasmsNCT00261703 · 439 enrolled · Portugal, Spain
  4. Jun 21, 2006Phase 2 study in Stomach NeoplasmsNCT00343239 · 59 enrolled · Turkey
  5. Sep 14, 2006Phase 4 study in Keratosis, ActinicNCT00377273 · 250 enrolled · United States
  6. Sep 27, 2006Phase 2 study in Stomach NeoplasmsNCT00382720 · 275 enrolled · United States, Belgium, France and more
  7. Nov 17, 2006Phase 3 study in Head and Neck NeoplasmsNCT00401323 · 568 enrolled · United States, Argentina, Australia and more
  8. May 9, 2007Phase 3 study in Carcinoma, HepatocellularNCT00471965 · 371 enrolled · China, Korea, Republic of, Taiwan and more
  9. Jul 10, 2007Phase 1 study in AdenocarcinomaNCT00499850 · 18 enrolled · Australia
  10. Nov 15, 2007Phase 2 study in Carcinoma, HepatocellularNCT00559455 · 38 enrolled · Korea, Republic of
  11. Jan 28, 20083 phase 2 studiesNCT00612495, NCT00611754, NCT00611507
  12. Oct 28, 2008Phase 2 study in Uterine NeoplasmsNCT00782041 · 11 enrolled · Thailand
  13. Sep 22, 2009Phase 3 study in Head and Neck NeoplasmsNCT00995293 · 240 enrolled · China
  14. Aug 14, 2013Phase 1 study in NeoplasmsNCT01930552 · 20 enrolled · China

TargetBeta

TYMS →read by rule
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
CapecitabineruleHoffmann-La Rochephase 4129
TegafurruleOtsukaphase 325

Studies

All 16 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01930552Neoplasms · China1CompletedDec 201420
NCT00995293Head and Neck Neoplasms · China3CompletedJan 26, 2018240
NCT00782041Uterine Neoplasms · Thailand2TerminatedAug 200311
NCT00612495Endometrial Neoplasms · France2Completed31
NCT00611754Head and Neck Neoplasms · France2Completed15
NCT00611507Stomach Neoplasms · Colombia2Completed21
NCT00559455Carcinoma, Hepatocellular · Korea, Republic of2CompletedJan 201038
NCT00499850Adenocarcinoma · Australia1CompletedJun 200618
NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more3CompletedMar 2010371
NCT00401323Head and Neck Neoplasms · United States, Argentina, Australia and more3CompletedJun 2003568
NCT00382720Stomach Neoplasms · United States, Belgium, France and more2CompletedApr 2010275
NCT00377273Keratosis, Actinic · United States4Completed250
NCT00343239Stomach Neoplasms · Turkey2CompletedMar 201259
NCT00261703Head and Neck Neoplasms · Portugal, Spain3CompletedJul 2010439
NCT00259402Esophageal Neoplasms · Spain2CompletedOct 200841
NCT00008281Colorectal Neoplasms · United States, Canada3UNKNOWN

How it is read

Names in the registry

  • “5-Fluorouracil”, 10 entries
  • “fluorouracil”, 9 entries
  • “Fluorouracil”, 8 entries
  • “5-fluorouracil”, 7 entries
  • “5-FU”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.